MBX Biosciences submits IND for MBX 4291, once-monthly GLP-1/GIP obesity prodrug

MBX Biosciences, Inc.

IND submitted to FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for obesity.
Designed for once-monthly administration to potentially improve adherence and GI tolerability.
Phase 1 trial expected to start Q3 2025 in healthy overweight volunteers.
Candidate developed using MBX's proprietary PEP platform technology.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.